Publication of the first study based on Chinese specific
population in Cell as a Chinese precision medicine company

OrigiMed’s research team is led by an experienced expert who returned from Harvard University, specialising on cancer genomic annotation and clinical transformation researches for more than a decade. We are the only bioinformatic analysis team recognized by the U.S. National Cancer Institute’s Clinical Proteomic Tumor Analysis Consortium (CPTAC) supported by Cancer MoonshotSM. Our team has published the first study based on Chinese specific population in Cell (IF: 36.2) as a Chinese precision medicine company.

To date, OrigiMed has partnered with over 500 Chinese hospitals and 97% of them are key oncology hospitals. Our research area ranges from more than 50 types of solid tumors, including lung cancer, gastric cancer, breast cancer, hepatobiliary cancer and sarcoma, to hematological malignancies. Our research team has published more than a dozen of studies in many renowned journals both internationally and locally. We have also initiated multiple real world studies.